Testing A New Treatment For Motor Neuron Disease
Grant number: 1005651 | Funding period: 2011 - 2013
ALS is a form of motor neuron disease that quickly renders people paralysed by killing off the nerves needed for muscle control. It affects people when they are 40-60 years old, and very few survive more than 5 years after diagnosis. Our team is testing a new therapeutic compound that we have already shown to delay paralysis in mice with ALS. The work we are currently undertaking will provide all the necessary information required before we are able to test our compound in people with ALS.
Related publications (3)
ALS-Associated TDP-43 Induces Endoplasmic Reticulum Stress, Which Drives Cytoplasmic TDP-43 Accumulation and Stress Granule Formation
Adam K Walker, Kai Y Soo, Vinod Sundaramoorthy, Sonam Parakh, Yi Ma, Manal A Farg, Robyn H Wallace, Peter J Crouch, Bradley J Turner, Malcolm K Horne, Julie D Atkin
Endogenous progesterone levels and frontotemporal dementia: modulation of TDP-43 and Tau levels in vitro and treatment of the A315T TARDBP mouse model
Theresa NT Dang, Carol Dobson-Stone, Elias N Glaros, Woojin S Kim, Marianne Hallupp, Lauren Bartley, Olivier Piguet, John R Hodges, Glenda M Halliday, Kay L Double, Peter R Schofield, Peter J Crouch, John BJ Kwok